TW216771B - - Google Patents

Info

Publication number
TW216771B
TW216771B TW080103889A TW80103889A TW216771B TW 216771 B TW216771 B TW 216771B TW 080103889 A TW080103889 A TW 080103889A TW 80103889 A TW80103889 A TW 80103889A TW 216771 B TW216771 B TW 216771B
Authority
TW
Taiwan
Prior art keywords
substances
neuronal
vincristine
morphological
evaluating
Prior art date
Application number
TW080103889A
Other languages
English (en)
Chinese (zh)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of TW216771B publication Critical patent/TW216771B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW080103889A 1990-05-22 1991-05-20 TW216771B (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (1)

Publication Number Publication Date
TW216771B true TW216771B (OSRAM) 1993-12-01

Family

ID=9396855

Family Applications (1)

Application Number Title Priority Date Filing Date
TW080103889A TW216771B (OSRAM) 1990-05-22 1991-05-20

Country Status (16)

Country Link
US (3) US5229389A (OSRAM)
EP (2) EP0655247B1 (OSRAM)
JP (2) JP2618115B2 (OSRAM)
KR (1) KR0181330B1 (OSRAM)
AT (2) ATE132369T1 (OSRAM)
BR (1) BR9105015A (OSRAM)
CA (2) CA2042974C (OSRAM)
CY (1) CY2283B1 (OSRAM)
DE (2) DE69132797T2 (OSRAM)
DK (2) DK0458696T3 (OSRAM)
FR (1) FR2662355B1 (OSRAM)
HU (1) HU208922B (OSRAM)
IE (1) IE911707A1 (OSRAM)
IL (3) IL112167A (OSRAM)
TW (1) TW216771B (OSRAM)
ZA (1) ZA913865B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2672213B1 (fr) 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
US6043251A (en) * 1995-10-26 2000-03-28 Sanofi Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyr idine for preparing drugs for treating amyotrophic lateral sclerosis
EP0890105B1 (en) * 1996-03-29 2006-11-22 The Trustees Of Boston University Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
WO1998033502A1 (fr) * 1997-02-03 1998-08-06 Sanofi-Synthelabo Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
DE69115989T2 (de) 1996-08-22
US5229389A (en) 1993-07-20
EP0458696B1 (fr) 1996-01-03
DE69115989D1 (de) 1996-02-15
DK0458696T3 (da) 1996-05-20
BR9105015A (pt) 1993-05-25
HUT59824A (en) 1992-07-28
US5468753A (en) 1995-11-21
CY2283B1 (en) 2003-07-04
EP0655247A1 (fr) 1995-05-31
IL98175A (en) 1996-01-19
CA2365832A1 (en) 1991-11-23
JPH09132535A (ja) 1997-05-20
JPH04226917A (ja) 1992-08-17
AU636488B2 (en) 1993-04-29
KR0181330B1 (ko) 1999-03-20
CA2365832C (en) 2007-08-07
IL112167A (en) 1996-01-31
HK1001471A1 (en) 1998-06-19
JP2954029B2 (ja) 1999-09-27
IE20011078A1 (en) 2002-03-20
HU911729D0 (en) 1991-12-30
EP0655247B1 (fr) 2001-10-31
EP0458696A2 (fr) 1991-11-27
JP2618115B2 (ja) 1997-06-11
HU208922B (en) 1994-02-28
IL98175A0 (en) 1992-06-21
EP0458696A3 (en) 1992-03-18
ATE207747T1 (de) 2001-11-15
FR2662355B1 (fr) 1994-11-10
DK0655247T3 (da) 2002-02-18
ZA913865B (en) 1992-02-26
KR910019617A (ko) 1991-12-19
IE911707A1 (en) 1991-12-04
DE69132797T2 (de) 2002-05-29
CA2042974C (en) 2002-09-17
ATE132369T1 (de) 1996-01-15
IL112167A0 (en) 1995-03-15
US5270320A (en) 1993-12-14
CA2042974A1 (en) 1991-11-22
AU7713391A (en) 1991-11-28
DE69132797D1 (de) 2001-12-06
FR2662355A1 (fr) 1991-11-29

Similar Documents

Publication Publication Date Title
TW216771B (OSRAM)
DE69100547D1 (de) Methode und Vorrichtung zum elektrochemischen Bearbeiten der Spritzöffnungen von Brennstoff-Einspritzdüsen.
DE3177156D1 (de) Guanin-verbindungen und ihre verwendung zur herstellung eines antivirusmittels.
IT8119488A0 (it) Apparato e metodo perl'interrogazione di materiali biologici.
DE69008705D1 (de) Aufzeichnungsflüssigkeit und Verfahren zur Tintenstrahl-Aufzeichnung mit dieser Flüssigkeit.
IT8124138A0 (it) Procedimento e apparecchio per determinare quantitativamente il livello di emoglobina in campioni biologici.
DE3582211D1 (de) Strahlungsempfindliches aufzeichnungsmaterial und verfahren zu seiner herstellung.
DE3764056D1 (de) Verfahren und vorrichtung zur aufzeichnung und/oder auswertung des bewegungsverhaltens von versuchstieren.
DE58907944D1 (de) Verfahren und Vorrichtung zum Herstellen von hochverdichteten zylindrischen Presslingen aus losem Halmgut.
Rickson et al. Social bases of farmers' responses to land degradation.
DE59106745D1 (de) Strahlungsempfindliches Gemisch, hiermit hergestelltes strahlungsempfindliches Aufzeichnungsmaterial und Verfahren zur Herstellung von Reliefaufzeichnungen.
DE3581378D1 (de) Senkrecht magnetisiertes aufzeichnungsmedium und verfahren zu seiner herstellung.
DE58903740D1 (de) Pulverfoermiger dentalwerkstoff, verfahren zu seiner herstellung und seine verwendung.
DE59000468D1 (de) Verfahren zur schnellen pruefung der wirksamkeit von agenzien auf mikroorganismen.
DE58905675D1 (de) Schichtwerkstoff oder schichtwerkstück und verfahren zu seiner herstellung.
DE3879754D1 (de) Hydrophiler zusatz zum zuechten von pilzen und verfahren zu seiner verwendung.
DE3865649D1 (de) Apatitfuellmaterial zur fluessigchromatografie und verfahren zu seiner herstellung.
DE68909526D1 (de) Mit fasern und dispergierten partikeln verstaerkter mullit-werkstoff und verfahren zu seiner herstellung.
DE3575122D1 (de) Vorrichtung zum belueften von stroemenden medien.
DE68903554D1 (de) Verfahren zur verminderung der axialen dispersion in einem von einem magnetfeld stabilisierten wirbelbett.
ATE9343T1 (de) 2,6-diethyl-3,5-dimethyl-2,3-dihydro-4h-pyran, verfahren zu seiner herstellung und seine verwendung zur frueherkennung, lokalisierung und bekaempfung von lasioderma serricorne f.
IT8024877A0 (it) Reagente e metodo per determinare l'aldolasi di tipo muscolare umano.
DE3871671D1 (de) Verfahren zum herstellen von uran- und/oder plutoniumnitrid, verwendbar als kernbrennstoffmaterial.
CS39089A3 (en) Method for preventing damages caused by chemical and/or biological harmful substances
Blundon Comparison of methods for evaluating construction equipment acquisition

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent